Pharma Franchise & PCD Opportunity: Market WIKLYONE, the Future of Diabetes Management

Contents of This Post:

• Pharma Growth Opportunities in Diabetes Care
• What is WIKLYONE (Trelagliptin-100)?
• Why WIKLYONE Stands Out in the Market?
• Pharma Franchise & PCD Opportunity with WIKLYONE
• Benefits of Partnering with Best Biotech
• Who Can Join Hands for WIKLYONE Marketing?
• Be Part of the Future of Diabetes Care

“Diabetes is common: about 1 in 9 adults worldwide has it. Nearly 77 million adults (above 18) in India are living with diabetes. Besides, 25 million are prediabetics. Furthermore, 50% do not know they have diabetes.”

Does it ring a bell?

Pharma Growth Opportunities in Diabetes Care

India is often called the diabetes capital of the world. According to the International Diabetes Federation (IDF), India already has over 100 million people living with diabetes, and the number is projected to grow sharply in the coming years. That means one in every ten adults in the country is managing diabetes, making it one of the biggest chronic health challenges in our market.

For pharma traders, stockists, and PCD partners, this rising prevalence creates a steady, long-term demand for anti-diabetic medicines. Unlike short-term therapies, diabetes treatment is lifelong — once prescribed, patients often continue treatment for years. This makes it a sustainable category with consistent repeat demand, ensuring regular orders from pharmacies and continuous prescription refills.

At Best Biotech, we understand what this means for you. That’s why we have launched WIKLYONE (Trelagliptin-100) – India’s first once-a-week anti-diabetic tablet available for PCD and franchise marketing. While Zuventus was the first to bring Trelagliptin into India, it remains in the ethical marketing space where the company handles sales and promotion with its own field force. But we are proud to be the first pharma PCD company to open this innovative medicine for franchise and distribution marketing across India, while also welcoming pharma importers from across the world to make Trelagliptin available on the global market, following regulatory guidelines countrywise.

Here’s the real difference for you: when you partner with us, you don’t just get a breakthrough product. You get the exclusive marketing rights for your region, full promotional support, and the best trade prices. We keep margins minimal at our end so that you, as our partner, can focus your resources on marketing, building distribution networks, and reaching stockists and retailers effectively.

With diabetes care shifting toward more convenient solutions, WIKLYONE positions you ahead of the curve.

What is WIKLYONE (Trelagliptin-100)?

WIKLYONE is India’s second brand of Trelagliptin-100, an innovative anti-diabetic medicine. What makes it different is its once-a-week dosage. Unlike most anti-diabetic medicines that patients take once or even twice a day, WIKLYONE requires only four tablets a month.

For patients, this means less pill fatigue, better treatment adherence, and fewer chances of forgetting doses. Besides, for doctors, it’s a practical solution they can confidently prescribe to improve patient compliance. And for you as a pharma distributor, stockist, or retailer – it’s a product with a strong USP that sells itself when introduced correctly.

Another factor that strengthens WIKLYONE’s position is growing patient demand for convenience. Nearly 50% of patients with chronic conditions like diabetes stop taking the medication and increase the disease burden by making way for complications. And the biggest reason for lack of treatment adherence is the pill burden. People forget to take their pills. Sometimes, they choose not to take their medicines because of the side effects they have to bear with regular medication. And sometimes, they simply think it is better to stop the medication to cut the total cost of medicines.

So, patients today want medicines that fit seamlessly into their routine, with fewer reminders, side effects and are also cost-friendly. By offering a weekly tablet instead of 30 daily doses, you present them with a unique, patient-friendly option that creates trust and loyalty.

In short, WIKLYONE isn’t just another product in your portfolio. Rather, it’s a standout innovation that attracts attention, opens conversations with prescribers, and builds quick acceptance in the market. So, for pharma professionals, this is exactly the kind of product that sets you apart from competitors.

Why WIKLYONE Stands Out in the Market?

The Indian anti-diabetic market is one of the fastest-growing therapeutic segments in pharma. According to industry reports, India has more than 77 million people living with diabetes, making it the second-largest diabetic population in the world. By 2045, this number is expected to cross 134 million.

Most of these patients rely on daily oral hypoglycemics. However, treatment adherence remains a big challenge. Research suggests that nearly 50% of diabetic patients fail to follow their prescribed medication schedule, which leads to poor blood sugar control. This is where Trelagliptin brings a breakthrough.

• Firstly, once-a-week dosage → Only 4 tablets per month, compared to 30, even 60 or more tablets (for some) of daily medications.
• Secondly, it offers better compliance → Studies show that reducing pill frequency improves adherence by up to 60%.
• Next, there exists a growing demand for convenient therapies → The Indian patient base is increasingly seeking simpler treatment routines.

What gives WIKLYONE a strategic edge is that it is India’s 2nd brand of Trelagliptin – and the first one available in PCD marketing. The pioneer brand, Zafatek (Zuventus), operates only through ethical marketing with its own sales team. That leaves Best Biotech’s WIKLYONE as the only opportunity for pharma traders, wholesalers, and retailers to market this innovation under monopoly rights in their region.

This means you not only get access to a high-potential product with proven demand but also enjoy the benefit of being an early entrant in your territory, giving you a competitive advantage before the market gets saturated.

The Business Opportunity with WIKLYONE:

(For pharma traders, wholesalers, retailers, stockists and PCD/franchise partners — a comprehensive guide)

If you want a product that talks to both patient needs and business realities, WIKLYONE checks both boxes. Below, we break down the opportunity you can tap into — market demand, commercial terms, promotional and supply support we offer, and a clear path to get started.

1) Market Potential — Why This Category Will Sell?

• Firstly, it is a large and growing market. In addition, India ranks among the world’s largest diabetes markets. That creates continuing, long-term demand for antidiabetic therapies across urban and semi-urban areas.
• Secondly, real patients need convenience. Many patients skip daily medicines because of “pill fatigue.” Also, studies show non-adherence affects a large portion of patients. So, a once-a-week option reduces that friction and therefore creates stronger physician interest and patient acceptance.
• Thirdly, Trelagliptin offer prescription-friendly USP. Doctors welcome patient-friendly regimens that improve adherence. So, when you detail WIKLYONE to prescribers, the once-weekly message stands out, making it easier to open conversations and build trials.
• Finally, we offer early-mover advantage for PCD partners. Best Biotech’s WIKLYONE becomes the first Trelagliptin brand available specifically for PCD/franchise marketing, which gives you a head start in territories where you secure rights.

2) Commercial Terms & Pricing Model — Structured to Let You Invest in Marketing

• Firstly, we offer trade-friendly pricing. We keep our markup minimal above manufacturing cost, so you receive highly competitive trade prices. That allows you to allocate a larger share of your budget to promotion and doctor detailing rather than absorbing high product costs.
• Secondly, you get monopoly (exclusive) rights by territory. We grant exclusive marketing/PCD rights for defined territories based on agreed purchase commitments and sales targets. That means you avoid intra-company competition in your zone when you meet performance commitments.
• Thirdly, we offer flexible ordering & MOQ (typical model) — you place an initial onboarding order, followed by periodic replenishment. We tailor MOQs to your scale. So, small stockists can start lean and larger distributors can opt for bigger allocation to secure lower per-unit cost. Besides, we are always ready to support all growing and already thriving pharma professionals. Our impartial treatment towards all small as well as large business partners makes us the best pharma company in India. Do not take our words for it. Hear what our franchisee partners have to say about our business relationships.
• Finally, we have a transparent margin structure. Because we price for trade-effectiveness, you can plan realistic distributor margins and set promotional budgets without squeezing profitability.

3) Promotional & Operational Support — What We Provide to Help You Sell

We don’t just supply product — we equip your marketing team to win with:

Firstly, we offer Marketing materials (ready-to-use):

• Product brochures, doctor monographs, pharma visual aids for doctor detailing and patient leaflets.
• Branded sample kits for doctor detailing (sample + patient leaflet).
• POS displays, shelf talkers, and MRP labels where applicable.
• Digital assets for WhatsApp, Facebook, and local ads, including static posts as well as videos for comprehensive views.

Secondly, we provide training & medical support:

• Product training webinars for your field staff and medical representatives.
• Slide decks and talking points to help with doctor detailing.
• Access to our medical affairs team for professional queries (on documented product info)

Thirdly, we help with Sales & launch support:

• Help with territory launch planning: KOL mapping, clinic lists, and pharmacy targeting.
• Promotional schemes and introductory offers to help you seed the market
• Periodic promotional material refreshes and campaign suggestions

Next, we help with Regulatory & technical documents, wherever possible and necessary:

• Product dossier summaries and batch certificates for legitimate distributor review.
• Stability and shelf-life information for pharmacy and hospital procurement teams.

Finally, we are known for our supply chain reliability:

• Scheduled production runs and priority allocation for verified PCD partners.
• Pack and batch traceability so you can assure retailers and hospitals.

4) Channel Strategies That Work (Practical Tactics for Faster Traction)

1. Firstly, target doctors first. Start with endocrinologists, diabetologists, and general physicians in urban clinics. Besides, offer sample kits and follow up for feedback.
2. Secondly, seed key pharmacies near hospitals. Hospital-adjacent pharmacies and high-footfall retail pharmacies convert trials fast.
3. Thirdly, use the PCD model smartly. Empower local medical reps to drive prescriptions while you support them with strong promotional collateral.
4. Next, leverage digital detailers. Short WhatsApp update packs for doctors and quick video explainers boost trial adoption.
5. Then, run limited-time patient awareness drives. Simple campaigns that explain once-a-week convenience can improve pharmacy sales and prescription switches.

5) Risk mitigation — what to consider and how we help

• Firstly, follow regulatory compliance. Follow all local marketing and prescription rules. We provide compliant material; you must use it responsibly.
• Secondly, maintain territorial performance. Maintain agreed sales targets to keep exclusivity. If targets slip, we’ll discuss corrective plans or adjust territory terms.
• Additionally, step forward for market education. Because Trelagliptin is new as a PCD option, expect an initial education phase. We support that with medical training and doctor outreach material.

6) Example partner onboarding (typical flow)

• Inquiry → share company profile and territory interest.
• Agreement → sign PCD/franchise agreement with defined territory, MOQ, and sales targets.
• Initial order → place onboarding order and receive products with promotional inputs.
• Launch support → We run product training for your team and provide digital assets.
• Ongoing supply → monthly/quarterly replenishments, performance reviews, and promotional refreshes.

Why Partner with Best Biotech On WIKLYONE?

What’s more, the market is shifting toward innovative, patient-friendly medicines. Doctors want options that improve adherence and reduce patient burden. WIKLYONE, with its once-a-week regimen, fits right into this evolving need. While most antidiabetic drugs require daily or even twice-daily dosing, Trelagliptin offers an edge: fewer doses, better compliance, and satisfied patients.

For you as a PCD partner, this isn’t just about stocking another diabetes medicine — it’s about stocking a differentiator that can help you stand out in your territory, win prescriber confidence, and build brand loyalty among patients.

• WIKLYONE gives you the first PCD access to Trelagliptin in India — an exclusive opportunity.
• Competitive trade pricing so you can invest in aggressive local marketing.
• Comprehensive promotional & medical support to shorten the adoption curve.
• Supply & documentation to satisfy retailers, hospital buyers and regulators.
• Monopoly rights that protect your investment when you meet targets.

Ready to explore? — Next steps

If this looks like the growth opportunity you want, let’s talk specifics: territory availability, MOQ, pricing, and launch support. DM us or email the Business Development team. We will share the partner pack and set up a one-to-one call to tailor terms for your market.

Note: All product promotions must follow local regulatory guidelines. WIKLYONE details and clinical use are for qualified professionals; patients should consult their diabetologist before changing therapy.

Who Can Join Hands for WIKLYONE Marketing?

WIKLYONE (Trelagliptin 100 mg) is a breakthrough product that opens new doors for pharma business partners. Here’s who can benefit the most:

Pharma PCD Distributors & Franchise Partners

If you already operate in the PCD business or plan to expand, WIKLYONE can add strength to your portfolio. With its distinct once-a-week dosage, you can present a differentiated offering to doctors and patients.

Wholesalers and Stockists

A product with long-term demand like Trelagliptin ensures fast movement and consistent repeat orders. Wholesalers and stockists can enjoy steady turnover with high market demand backing the product.

Retailers & Pharmacy Chains

Retail counters thrive on trusted, high-demand medicines. WIKLYONE gives you a unique product with strong clinical relevance, helping you serve patients better while improving your margins.

Marketing Professionals & New Entrepreneurs

If you’re planning to step into the pharma business, WIKLYONE is a smart product to begin with. Best Biotech supports partners with monopoly rights, promotional material, and competitive pricing, so you can focus on building your brand in your territory.

Hospital Procurement Teams

With diabetes being one of the most common conditions treated in hospitals, adding WIKLYONE to hospital pharmacies ensures the availability of an advanced once-weekly option for patients, while also strengthening trust with prescribing doctors.

By joining hands with Best Biotech, partners not only get a high-potential product but also end-to-end support to market and distribute it effectively.

Be a Part of the Future of Diabetes Care

Diabetes management is evolving rapidly, and once-weekly therapies like WIKLYONE represent the next big leap in patient care. Unlike the traditional model where patients juggle daily or even twice-daily pills, WIKLYONE simplifies treatment to just one pill a week. This shift doesn’t just improve patient adherence—it reshapes the way diabetes care is delivered.

As a pharma trader, distributor, retailer, or stockist, being associated with such an innovation means you aren’t just selling a product—you’re contributing to a movement that reduces pill fatigue, improves patient quality of life, and supports better long-term outcomes.

Best Biotech takes pride in making WIKLYONE accessible for PCD marketing, giving business partners the first-mover advantage in this growing segment. With diabetes cases in India projected to cross 134 million by 2045 (IDF Diabetes Atlas, 2023), the demand for advanced and convenient treatment options will only rise.

Now is the time to step forward and secure your place in the future of diabetes care. With our strong supply chain, competitive pricing, monopoly rights, and complete promotional support, we ensure our partners are equipped for success.

Partner with Best Biotech today and bring WIKLYONE to your market. Together, let’s redefine diabetes care—one week at a time.

Related Posts:

1. Is Wiklyone right for you
2. WIKLYONE-100 TABLETS
3. WIKLYONE: Life-Changing First-of-its Kind Diabetes Medicine
4. Why Pharma Exhibitions Matter: 9 Top Reasons to Attend Next Pharma Expo
5. Once a Week Medicine for Diabetes: WIKLYONE (Trelagliptin): How it Works?

Quick Links:

1. Pharma Exhibition at Guwahati ( Assam )
2. Downloads Division Wise Products
3. Video Library
4. Best Cardia Division Products
5. Soqute Division Products